Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENDP Endo International		$0.45	$0.28 ▼ $7.07	$141K	1.15	28.19 million shs	9,967 shs
JNJ Johnson & Johnson	$154.42 -1.2%	$159.24	$140.68 ▼ $169.99	$371.54B	0.49	7.92 million shs	7.32 million shs
MRNA Moderna	$27.03 -5.3%	$29.77	$23.15 ▼ $170.47	$10.45B	2.23	7.42 million shs	14.87 million shs
NVAX Novavax	$6.41 -3.9%	$7.04	$4.29 ▼ $23.86	$1.03B	3.15	8.36 million shs	5.62 million shs
PFE Pfizer	$23.91 -2.1%	$24.44	$20.92 ▼ $31.54	$135.59B	0.67	40.91 million shs	44.43 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENDP Endo International	0.00%	0.00%	0.00%	0.00%	0.00%
JNJ Johnson & Johnson	+0.27%	+0.63%	-5.77%	+2.32%	+8.10%
MRNA Moderna	+2.59%	+7.61%	+0.67%	-30.46%	-74.13%
NVAX Novavax	+3.89%	-10.88%	+4.06%	-25.97%	+54.04%
PFE Pfizer	+2.56%	+9.07%	-3.73%	-9.24%	-4.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENDP Endo International	0.4326 of 5 stars	0.0	0.0	0.0	3.5	1.1	1.7	0.0
JNJ Johnson & Johnson	4.3103 of 5 stars	2.3	3.0	4.2	3.9	2.7	2.5	0.6
MRNA Moderna	4.2602 of 5 stars	4.0	1.0	0.0	4.6	2.7	2.5	0.6
NVAX Novavax	3.6228 of 5 stars	3.2	1.0	0.0	4.7	3.0	0.8	0.6
PFE Pfizer	4.9773 of 5 stars	3.3	3.0	4.2	4.3	3.1	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENDP Endo International	0.00	N/A	N/A	N/A
JNJ Johnson & Johnson	2.63	Moderate Buy	$171.82	11.27% Upside
MRNA Moderna	2.04	Hold	$58.70	117.17% Upside
NVAX Novavax	2.43	Hold	$18.00	180.81% Upside
PFE Pfizer	2.53	Moderate Buy	$29.64	23.99% Upside

Current Analyst Ratings Breakdown

Latest NVAX, PFE, MRNA, ENDP, and JNJ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/30/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$24.00 ➝ $25.00
4/24/2025	JNJ Johnson & Johnson	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/22/2025	PFE Pfizer	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Neutral	$24.00
4/17/2025	JNJ Johnson & Johnson	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$166.00 ➝ $165.00
4/17/2025	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
4/16/2025	JNJ Johnson & Johnson	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
4/16/2025	JNJ Johnson & Johnson	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00 ➝ $181.00
4/16/2025	JNJ Johnson & Johnson	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$164.00 ➝ $169.00
4/14/2025	JNJ Johnson & Johnson	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$165.00 ➝ $162.00
4/10/2025	JNJ Johnson & Johnson	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$171.00 ➝ $159.00
4/9/2025	JNJ Johnson & Johnson	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$163.00 ➝ $164.00

(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENDP Endo International	$2.99B	0.00	N/A	0.06	($13.60) per share	0.00
JNJ Johnson & Johnson	$89.33B	4.16	$12.69 per share	12.17	$29.69 per share	5.20
MRNA Moderna	$3.20B	3.27	N/A	N/A	$28.33 per share	0.95
NVAX Novavax	$682.16M	1.51	N/A	N/A	($6.04) per share	-1.06
PFE Pfizer	$62.46B	2.17	$3.75 per share	6.38	$15.81 per share	1.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENDP Endo International	-$613.24M	-$11.07	N/A	0.00	N/A	-93.31%	-34.25%	6.72%	N/A
JNJ Johnson & Johnson	$14.07B	$8.99	23.22	13.95	2.56	18.20%	34.24%	13.63%	7/16/2025 (Estimated)
MRNA Moderna	-$3.56B	-$9.28	N/A	N/A	N/A	-110.04%	-28.74%	-21.83%	5/1/2025 (Estimated)
NVAX Novavax	-$545.06M	-$1.33	N/A	80.13	2.85	-32.18%	N/A	-17.05%	5/9/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	16.96	7.89	0.64	12.62%	19.47%	8.09%	N/A

Latest NVAX, PFE, MRNA, ENDP, and JNJ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q1 2025	NVAX Novavax	$0.19	N/A	N/A	N/A	$204.08 million	N/A
5/1/2025	Q1 2025	MRNA Moderna	-$2.92	-$2.52	+$0.40	-$2.52	$130.35 million	$108.00 million
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/15/2025	Q1 2025	JNJ Johnson & Johnson	$2.59	$2.77	+$0.18	$4.54	$21.65 billion	$21.89 billion
2/27/2025	Q4 2024	NVAX Novavax	-$0.75	-$0.51	+$0.24	-$0.51	$85.48 million	$88.31 million
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENDP Endo International	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$5.20	3.37%	+5.43%	57.84%	64 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	7.19%	+2.50%	124.64%	16 Years

Latest NVAX, PFE, MRNA, ENDP, and JNJ Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
4/15/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.37%	5/27/2025	5/27/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENDP Endo International	N/A	1.86	1.62
JNJ Johnson & Johnson	0.43	1.11	0.86
MRNA Moderna	N/A	3.67	3.62
NVAX Novavax	N/A	0.93	0.93
PFE Pfizer	0.63	1.00	0.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENDP Endo International	80.39%
JNJ Johnson & Johnson	69.55%
MRNA Moderna	75.33%
NVAX Novavax	53.04%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ENDP Endo International	1.20%
JNJ Johnson & Johnson	0.16%
MRNA Moderna	11.00%
NVAX Novavax	1.00%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENDP Endo International	3,103	235.14 million	232.32 million	No Data
JNJ Johnson & Johnson	152,700	2.41 billion	2.40 billion	Optionable
MRNA Moderna	3,900	386.62 million	324.40 million	Optionable
NVAX Novavax	1,990	160.84 million	158.58 million	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable

NVAX, PFE, MRNA, ENDP, and JNJ Headlines

Recent News About These Companies

Arvinas (ARVN) Halts Development of Cancer Drug with Pfizer | ARVN Stock News

May 1 at 3:07 PM | gurufocus.com

Pfizer (NYSE:PFE) Stock Price Up 2% After Better-Than-Expected Earnings

May 1 at 11:17 AM | marketbeat.com

Do Wall Street Analysts Like Pfizer Stock?

May 1 at 10:19 AM | msn.com

UBS Group Boosts Pfizer (NYSE:PFE) Price Target to $25.00

May 1 at 10:14 AM | marketbeat.com

Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks

May 1 at 9:40 AM | zacks.com

Becker Capital Management Inc. Cuts Stake in Pfizer Inc. (NYSE:PFE)

May 1 at 7:35 AM | marketbeat.com

Comerica Bank Lowers Stock Holdings in Pfizer Inc. (NYSE:PFE)

May 1 at 7:23 AM | marketbeat.com

3 High-Yield Dividend Stocks That Could Rally Near 52-Week Lows (PFE)

May 1 at 7:15 AM | marketbeat.com

Want Safe Dividend Income in 2025 and Beyond? Invest in the Following 3 Ultra-High-Yield Stocks.

May 1 at 4:15 AM | fool.com

Could Pfizer’s 7.1% Yield Be A Trap?

May 1 at 3:15 AM | talkmarkets.com

Pfizer Expands Cost-Cutting Measures, Reaffirms Outlook

May 1 at 1:54 AM | wsj.com

Pfizer (NYSE:PFE) Trading 3.6% Higher on Strong Earnings

May 1 at 1:41 AM | americanbankingnews.com

Pfizer Inc (PFE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline and Strategic Growth

April 30 at 7:17 PM | finance.yahoo.com

Pfizer Inc. (NYSE:PFE) Q1 2025 Earnings Call Transcript

April 30 at 7:17 PM | msn.com

Pfizer CEO Albert Bourla Emphasizes National Security In US Drug Manufacturing

April 30 at 5:36 PM | benzinga.com

Top Pharmaceutical Stocks To Consider - April 29th

April 30 at 2:31 PM | marketbeat.com

Best Manufacturing Stocks To Watch Now - April 29th

April 30 at 2:30 PM | marketbeat.com

Pfizer (PFE) Rating Upgraded: Signs of Stabilization Amid Strategic Shifts

April 30 at 12:58 PM | gurufocus.com

Pfizer (NYSE:PFE) Releases Earnings Results, Beats Estimates By $0.25 EPS

April 30 at 11:39 AM | marketbeat.com

Pfizer (NYSE:PFE) Trading 3.6% Higher on Earnings Beat

April 30 at 11:21 AM | marketbeat.com

Boost Your Portfolio With These 5 Low Price-to-Book Stocks

April 30 at 10:10 AM | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Are Tariffs Threatening Disney’s Comeback Story?
By Jea Yu | April 9, 2025
View Are Tariffs Threatening Disney’s Comeback Story?
Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Signs of a more buyer-friendly housing market emerge for the spring homebuying season
By The Associated Press | April 6, 2025
View Signs of a more buyer-friendly housing market emerge for the spring homebuying season
3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
By Leo Miller | April 28, 2025
View 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?
By Chris Markoch | April 16, 2025
View Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?

NVAX, PFE, MRNA, ENDP, and JNJ Company Descriptions

Endo International NASDAQ:ENDP

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Johnson & Johnson NYSE:JNJ

$154.42 -1.89 (-1.21%)

Closing price 03:59 PM Eastern

Extended Trading

$154.50 +0.08 (+0.05%)

As of 05:33 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Moderna NASDAQ:MRNA

$27.03 -1.51 (-5.29%)

Closing price 04:00 PM Eastern

Extended Trading

$27.14 +0.11 (+0.41%)

As of 05:32 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Novavax NASDAQ:NVAX

$6.41 -0.26 (-3.90%)

Closing price 04:00 PM Eastern

Extended Trading

$6.42 +0.01 (+0.16%)

As of 05:25 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Pfizer NYSE:PFE

$23.91 -0.50 (-2.06%)

Closing price 03:59 PM Eastern

Extended Trading

$23.97 +0.06 (+0.26%)

As of 05:33 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVAX, PFE, MRNA, ENDP, and JNJ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVAX, PFE, MRNA, ENDP, and JNJ Earnings

Compare Dividends

Latest NVAX, PFE, MRNA, ENDP, and JNJ Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVAX, PFE, MRNA, ENDP, and JNJ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NVAX, PFE, MRNA, ENDP, and JNJ Company Descriptions

Endo International NASDAQ:ENDP

Johnson & Johnson NYSE:JNJ

Moderna NASDAQ:MRNA

Novavax NASDAQ:NVAX

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools